Tech Company Financing Transactions
VerImmune Funding Round
On 9/20/2023, VerImmune raised $3 million in funding from Proxima Ventures, Gaingels and Mana Ventures.
Transaction Overview
Company Name
Announced On
9/20/2023
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds will be used to accelerate GLP/GMP activities towards an IND for VerImmune's lead product candidate VERI-101.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7144 13th PL NW 2200
Washington, DC 20012
USA
Washington, DC 20012
USA
Phone
Website
Email Address
Overview
Founded in Baltimore Maryland, and now located at JLAB@Washington DC, VerImmune is biotechnology company developing a novel first-in-class cancer therapy known as Anti-tumor Immune Redirection (AIR). This strategy utilizes a proprietary virus-inspired particle (ViP) technology platform that redirects pre-existing pathogenic or childhood vaccine immune memory towards tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joshua Wang
Chief Operating Officer
John Troyer
Browse more venture capital transactions:
Prev: 9/20/2023: Corti venture capital transaction
Next: 9/20/2023: Meyers Manx venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries on this site are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs